tokens: Concomitant inactivation of Chk2 and p53 in breast cancer has been recorded by others [ 59 ] , and the finding that a somatic mutation may generate a " growth advantage " in tumor cells already harboring a germline CHEK2 mutation may not implicate an effect on drug sensitivity in tumors not yet exposed to cytotoxic compounds .